A Crossover, Randomized, Open-label, Comparison Study Between DWJ1525 and the Concomitant Use of DWP16001 and DWC202101 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers
Latest Information Update: 12 Jul 2022
Price :
$35 *
At a glance
- Drugs DWC 202101 (Primary) ; Enavogliflozin (Primary) ; Enavogliflozin/metformin hydrochloride (Primary)
- Indications Metabolic disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 07 Jul 2022 Status changed from not yet recruiting to completed.
- 21 Jan 2022 New trial record